Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Heterogeneity has been demonstrated to be a predictor of treatment failure and drug resistance. Our study aimed to investigate imaging parameters, including tumor heterogeneity, as prognostic factors of response to 500 mg fulvestrant using 18F-FDG PET/CT. Twenty-seven estrogen receptor (HR)-positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yannan, Liu, Cheng, Zhang, Yingjian, Gong, Chengcheng, Li, Yi, Xie, Yizhao, Wu, Bingrui, Yang, Zhongyi, Wang, Biyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160449/
https://www.ncbi.nlm.nih.gov/pubmed/30262849
http://dx.doi.org/10.1038/s41598-018-32745-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160449/
https://www.ncbi.nlm.nih.gov/pubmed/30262849
http://dx.doi.org/10.1038/s41598-018-32745-z

Ejemplares similares